

# Sofosbuvir improves renal safety in patients with chronic hep C

11 May 2018



(HealthDay)—Sofosbuvir-based treatment appears to guarantee renal safety for patients with chronic hepatitis C virus over one year of follow-up, according to a study published online May 7 in the *Journal of Clinical Pharmacy and Therapeutics*.

Thalia Medeiros, from the Universidade Federal Fluminense in Niterói, Brazil, and colleagues evaluated renal biomarkers among 94 chronic hepatitis C patients treated with sofosbuvir therapy. Urine samples were collected at the end of therapy, after 12 weeks sustained [virological response](#), and one year post-treatment.

The researchers found that 98.9 percent of patients reached sustained virological response. In patients with [glomerular filtration rate](#) (GFR)  $\leq 45$  mL/min/1.73 m<sup>2</sup> there was significant improvement in renal biomarkers, as indicated by a progressive increase in mean GFR values until one year. There was no evidence of tubular dysfunction. There was no change in renal biomarkers among patients with baseline GFR

APA citation: Sofosbuvir improves renal safety in patients with chronic hep C (2018, May 11) retrieved 26 June 2019 from <https://medicalxpress.com/news/2018-05-sofosbuvir-renal-safety-patients-chronic.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*